慢性阻塞性肺疾病中基于表型/内型的治疗：潜在的经济影响 - Suppr | 超能文献

Phenotype/endotype-driven therapy in COPD: potential economic implications.

作者信息

Antoniu Sabina A

出版信息

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):421-3. doi: 10.1586/14737167.2013.815402.

DOI:10.1586/14737167.2013.815402

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Phenotype/endotype-driven therapy in COPD: potential economic implications.慢性阻塞性肺疾病中基于表型/内型的治疗：潜在的经济影响

Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):421-3. doi: 10.1586/14737167.2013.815402.

2

[Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany].[罗氟司特联合长效支气管扩张剂用于重度和极重度慢性阻塞性肺疾病患者的管理。德国的成本效益分析]

Dtsch Med Wochenschr. 2013 Jan;138(4):119-25. doi: 10.1055/s-0032-1327416. Epub 2013 Jan 15.

3

The objective evaluation of obstructive pulmonary diseases with spirometry.通过肺量计对阻塞性肺疾病进行客观评估。

Int J Chron Obstruct Pulmon Dis. 2016 Aug 25;11:2009-15. doi: 10.2147/COPD.S113774. eCollection 2016.

4

Roflumilast in COPD: a Brazilian perspective.罗氟司特治疗慢性阻塞性肺疾病：巴西视角

Int J Chron Obstruct Pulmon Dis. 2015 Sep 8;10:1853-5. doi: 10.2147/COPD.S64455. eCollection 2015.

5

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.罗氟司特/噻托溴铵联合治疗与噻托溴铵单药治疗重度至极重度 COPD 的成本效果分析。

J Med Econ. 2011;14(6):805-15. doi: 10.3111/13696998.2011.623204. Epub 2011 Oct 12.

6

Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.罗氟司特对慢性阻塞性肺疾病（COPD）急性加重、医疗保健利用及成本的影响：以老年医保优势人群为主的研究

Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:565-76. doi: 10.2147/COPD.S79025. eCollection 2015.

7

[Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].[罗氟司特：慢性阻塞性肺疾病炎症治疗新选择的临床综述]

Arch Bronconeumol. 2010 Nov;46 Suppl 9:8-11. doi: 10.1016/S0300-2896(10)70047-8.

8

Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.在英国，对于患有与慢性支气管炎相关的重度和极重度慢性阻塞性肺疾病（COPD）的患者，罗氟司特作为三联吸入疗法附加治疗与三联吸入疗法相比的成本效益。

Int J Chron Obstruct Pulmon Dis. 2018 Sep 3;13:2707-2720. doi: 10.2147/COPD.S167730. eCollection 2018.

9

[Phosphodiesterase-4 inhibitors: roflumilast].[磷酸二酯酶-4抑制剂：罗氟司特]

Rev Clin Esp. 2011 Mar;211 Suppl 2:22-30. doi: 10.1016/S0014-2565(11)70008-X.

10

Roflumilast: a novel treatment for chronic obstructive pulmonary disease.罗氟司特：一种用于治疗慢性阻塞性肺疾病的新型药物。

Ann Pharmacother. 2012 Apr;46(4):521-9. doi: 10.1345/aph.1Q646. Epub 2012 Mar 20.

引用本文的文献

1

Precision medicine in COPD: where are we and where do we need to go?慢性阻塞性肺疾病精准医学：我们身在何处，又需要去往何方？

Eur Respir Rev. 2018 Aug 1;27(149). doi: 10.1183/16000617.0022-2018. Print 2018 Sep 30.